The screening facility of Marseille-Luminy (PCML) is linked to several topics in antiviral research and drug design.
Our service is highly flexible and allows external users to choose from several research services (collaboration, agreement service,…). PCML offers its expertise and know-how at various levels:
PCML also offers the possibility to screen for compounds likely to inhibit the catalytic activity of a specific enzyme or to screen for other compounds using our enzyme catalog.
PCML is a partner of the multi-site Antiviral Drug Design Platform (AD2P) facility. This collaborative network, labelled Aix-Marseille technological platform, was launched in 2005 and consists of PCML, the viral screening facility of Marseille-Timone (PCVMT, resp. X.de Lamballerie) and the Interaction, Dynamics and Drug-design facility (INT-3D, resp. Xavier Morelli). PCML is also involved into the Marseille Screening Center (MaSC) (https://www.afmb.univ-mrs.fr/MaSC/ ; https://www.ibisa.net/plateformes/marseille-screening-center-masc-709.html), labeled by IBISA in 2022. Such a federation of complementary expertise creates a dynamic interface for project development and optimization.
Academia and industries
To be defined from the service requested.
PCML has a current pattent in valorisation by the SATT-SE (Dengue antivirals: new active chemical entities against the Dengue virus n°EP13305019.5 (20th June 2013)), targeting the 4 serotypes of the Dengue virus and others members of the Flavivirus family, human pathogens, as the Zika virus.